Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome) (TTP registry)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01257269|
Recruitment Status : Recruiting
First Posted : December 9, 2010
Last Update Posted : July 30, 2019
Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the microvasculature with von Willebrand factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) deficiency which is the result of compound heterozygous or homozygous ADAMTS13 gene mutations.
Although considered a monogenic disorder the clinical presentation in Upshaw-Schulman syndrome patients varies considerably without an apparent genotype-phenotype correlation. In 2006 we have initiated a registry for patients with Upshaw-Schulman syndrome and their family members to identify possible triggers of acute bouts of TTP, to document individual clinical courses and treatment requirements as well as possible side effects of long standing plasma substitution, e.g. alloantibody formation or viral infections.
|Condition or disease||Intervention/treatment|
|Thrombotic Thrombocytopenic Purpura Congenital Thrombotic Thrombocytopenic Purpura Familial Thrombotic Thrombocytopenic Purpura Thrombotic Thrombocytopenic Purpura, Congenital Upshaw-Schulman Syndrome||Other: Observation|
Thrombocytopenia and microangiopathic hemolytic anemia together with a severely deficient ADAMTS13 activity confirm the diagnosis of acute thrombotic thrombocytopenic purpura (TTP). Today two forms of classical TTP are distinguished. The acquired form is caused by circulating auto-antibodies, mainly Immunoglobulin G (IgG), inhibiting ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) activity. In contrast, hereditary TTP, also known as Upshaw-Schulman syndrome (USS); #274150 Online Mendelian Inheritance in Man (OMIM), is the result of severe constitutional deficiency of ADAMTS13 due to compound heterozygous or homozygous mutations in the ADAMTS13 gene.
The clinical course of USS is variable with rather mild courses in some of the patients requiring plasma infusions only in special situations (i.e. pregnancy), while in others severe courses with important sequelae and even death in early childhood occur. The reasons for the variable clinical presentation and treatment requirements have not been elucidated. It seems likely, that additional, hitherto unidentified factors besides severe ADAMTS13 deficiency modify the clinical course.
At present, the clinical symptoms and laboratory values on which to base treatment regimens for hereditary TTP are poorly understood. Furthermore, increasing awareness of hereditary TTP results in rising numbers of patients in need of treatment and/or prophylaxis. However, currently very little is known on side effects of long standing plasma substitution. Alloimmunization with the formation of antibodies acting as inhibitors of treatment are well known in other congenital coagulation factor deficiencies (e.g. hemophilia A), but so far no case of treated hereditary TTP with subsequent antibody formation has been reported. It is the aim of the hereditary TTP Registry to provide information on the clinical course of the disease in as many patients as possible and therefore help to establish recommendations on the necessity, modalities, and risks of prophylactic plasma therapy in patients with hereditary TTP. Furthermore, it will help to gain detailed insight into triggers and risk factors of acute bouts of TTP.
Moreover, the hereditary TTP Registry will provide information for family members on their risk to develop TTP-like or TTP-related disorders.
Primary objective: Collection of as much information as possible on the clinical presentation, disease course, disease-modifying factors, and treatment modalities of patients suffering from hereditary thrombotic thrombocytopenic purpura (TTP).
Secondary objective: To document potential adversary effects of (long-term) plasma treatment in patients with hereditary thrombotic thrombocytopenic purpura (TTP).
The TTP Registry is designed to collect both retrospective and prospective clinical, molecular, and observational data on patients with confirmed or suspected hereditary TTP. Additionally, the Registry will collect data from family members of TTP patients enrolled in the Registry. The Registry will enroll as many confirmed or suspected hereditary TTP patients and their family members as possible; there is no cap on enrollment. The Registry enrollment and follow-up periods are open-ended. The endpoints for patients with confirmed or suspected hereditary TTP and family members are death or withdrawal of consent.
|Study Type :||Observational|
|Estimated Enrollment :||450 participants|
|Official Title:||Thrombotic Thrombocytopenic Purpura Registry - A Prospective Observational Study for Patients Suffering From Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)|
|Study Start Date :||October 2006|
|Estimated Primary Completion Date :||October 2030|
|Estimated Study Completion Date :||October 2030|
Patients with confirmed hereditary TTP due to congenital ADAMTS13 deficiency
No interventions planned: treatment of patients at the discretion of the treating/responsible physician
Family members of patients with confirmed hereditary TTP
No interventions planned: treatment of patients at the discretion of the treating/responsible physician
- Clinical presentation and disease course in hereditary TTP [ Time Frame: every year until death ]
- Identification of disease-modifying factors, including genotype-phenotype correlation [ Time Frame: every year until death ]
- Treatment requirements in hereditary TTP patients [ Time Frame: every year until death ]
- Documentation of potential adversary effects of (long-term) plasma treatment [ Time Frame: every year until death ]
- Mortality of hereditary TTP [ Time Frame: every year until death ]
- Clinical course in family members [ Time Frame: every year until death ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01257269
|Contact: Johanna A Kremer Hovinga, MD||+41 31 632 02 firstname.lastname@example.org|
|Contact: Erika Tarasco, Ph.D.||+41 31 632 56 email@example.com|
|United States, Oklahoma|
|University of Oklahoma Health Sciences Center, Department of Medicine, PO Box 26901||Recruiting|
|Oklahoma City, Oklahoma, United States, 73126-0901|
|Contact: James N. George, M.D. 405-271-4222 firstname.lastname@example.org|
|Principal Investigator: James N. George, M.D.|
|Medical University of Vienna, Department of Medicine 1, Div. Hematology and Hemostasis Waehringer Guertel 18-20||Recruiting|
|Vienna, Austria, A-1090|
|Contact: Paul N. Knoebl, M.D. +43 1 40400 4410 email@example.com|
|Principal Investigator: Paul N. Knoebl, M.D.|
|Institute of Hematology and Blood Transfusion, Coagulation Laboratory, U nemocnice 1||Recruiting|
|Prague 2, Czechia, CZ-12820|
|Contact: Ingrid Hrachovinova, Ph.D. +420 2 2197 271 Ingrid.Hrachovinova@uhkt.cz|
|Principal Investigator: Ingrid Hrachovinova, Ph.D.|
|University Medical Center Hamburg-Eppendorf, Department of Pediatric Hematology and Oncology, Martinistr 52||Not yet recruiting|
|Hamburg, Germany, D-20246|
|Contact: Reinhard Schneppenheim, M.D., Ph.D. +49 40 7410 54270 firstname.lastname@example.org|
|Principal Investigator: Reinhard Schneppenheim, M.D., Ph.D.|
|Nara Medical University, Department of Blood Transfusion Medicine, Shijyo-cho 840||Recruiting|
|Kashihara city, Nara, Japan, 634-8522|
|Contact: Yoshihiro Fujimura, M.D. +81 744 22 3051 ext 3289 email@example.com|
|Principal Investigator: Yoshihiro Fujimura, M.D.|
|Trondheim University St Olavs Hospital, Department of Hematology, PO Box 3250 Sluppen||Recruiting|
|Trondheim, Norway, NO-7006|
|Contact: Petter Quist-Paulsen, M.D., Ph.D. +47 815 55 850 Petter.Quist-Paulsen@stolav.no|
|Contact: Anne-Sophie von Krogh, M.D. +47 815 55 850 Anne-Sophie.von.Krogh@stolav.no|
|Principal Investigator: Petter Quist-Paulsen, M.D.,Ph.D.|
|Sub-Investigator: Anne-Sophie von Krogh, M.D.|
|University Clinic of Hematology and Central Hematology Laboratory, Bern University Hospital and the University of Bern, Inselspital||Recruiting|
|Bern, Switzerland, 3010|
|Contact: Johanna A Kremer Hovinga, MD +41 31 632 02 65 firstname.lastname@example.org|
|Contact: Isabella Aebi, BMA +41 31 632 77 16 email@example.com|
|Principal Investigator: Johanna A Kremer Hovinga, MD|
|Study Chair:||Johanna A Kremer Hovinga, MD||University Clinic of Hematology and Central Hematology Laboratory, Bern University Hospital and the University of Bern, Inselspital|
|Study Chair:||Bernhard Lämmle, M.D.||University Medical Center, Center for Thrombosis and Hemostasis, Mainz, Germany|
|Study Chair:||Yoshihiro Fujimura, M.D.||Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan|
|Study Chair:||Ingrid Hrachovinova, Ph.D.||Institute of Hematology and Blood Transfusion, Coagulation Laboratory, Prague, Czech Republic|
|Study Chair:||Petter Quist-Paulsen, M.D., Ph.D.||Department of Hematology, St Olavs Hospital, 7006 Trondheim, Norway|
|Study Chair:||Reinhard Schneppenheim, M.D., Ph.D.||Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany|
|Study Chair:||James N. George, MD||University of Oklahoma Health Sciences Center, Department of Medicine, United States of America|
|Study Chair:||Paul N Knoebl, MD||Medical University of Vienna, Div. Hematology and Hemostasis, Austria|